Plain-English translation of NCT06341400 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of two medications: RC48-ADC and toripalimab, given as an injectable treatment before and after bladder cancer surgery. The trial includes 55 patients with muscle-invasive bladder cancer who cannot receive or choose not to receive the standard cisplatin-based chemotherapy. Researchers want to see if this medication combination can help destroy cancer cells and improve outcomes for this group of patients.
Standard chemotherapy (cisplatin) is highly effective for bladder cancer, but many patients cannot tolerate it due to kidney problems, hearing loss, nerve damage, or other side effects. This trial exists to find an alternative treatment option that may work for patients who are ineligible for or refusing standard chemotherapy.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions (injections into your vein) of the two medications every 2 weeks for 4 cycles before surgery, then have your bladder surgically removed. After surgery, you would continue receiving the same medications every 2 weeks for 8 more cycles. Throughout the trial, you would have regular follow-up visits at 3 months after surgery and then every 3 to 6 months to check how you're doing, with blood tests and imaging scans to monitor your cancer and any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China